

# Viive M Howell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3523632/publications.pdf>

Version: 2024-02-01

57  
papers

1,449  
citations

361413

20  
h-index

345221

36  
g-index

58  
all docs

58  
docs citations

58  
times ranked

2478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential effects of radiation fractionation regimens on glioblastoma. <i>Radiation Oncology</i> , 2022, 17, 17.	2.7	6
2	Are In Vitro Human Bloodâ€“Brainâ€“Tumor-Barrier Suitable Replacements for In Vivo Models of Brain Permeability for Novel Therapeutics?. <i>Cancers</i> , 2021, 13, 955.	3.7	21
3	Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 633210.	2.8	30
4	Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2700.	2.4	5
5	Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4651.	3.7	5
6	Overlooked potential of positrons in cancer therapy. <i>Scientific Reports</i> , 2021, 11, 2475.	3.3	4
7	Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4806.	4.1	14
8	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. <i>The Cochrane Library</i> , 2020, 2020, CD013238.	2.8	19
9	<i>ALK</i> -Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration <i>ALK</i> -Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020, 25, 641-649.	3.7	8
10	Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 237.	2.8	22
11	Why the dual origins of high grade serous ovarian cancer matter. <i>Nature Communications</i> , 2020, 11, 1200.	12.8	3
12	Temporal and spatial modulation of the tumor and systemic immune response in the murine G1261 glioma model. <i>PLoS ONE</i> , 2020, 15, e0226444.	2.5	16
13	Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1539-1542.	1.0	6
14	A multicenter study of thromboembolic events among patients diagnosed with <i>ROS1</i> -rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 34-40.	2.0	27
15	Expression of long noncoding RNAs in cancer-associated fibroblasts linked to patient survival in ovarian cancer. <i>Cancer Science</i> , 2020, 111, 1805-1817.	3.9	25
16	Matching treatment strategies to clinical phenotype: Biomarker-driven selection for neoadjuvant therapy in pancreatic cancer.. <i>Hpb</i> , 2019, 21, S200.	0.3	1
17	Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 218-224.	1.0	22
18	Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer ( <i>ALK</i> + NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e275-e282.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Acinar cell density at the pancreatic resection margin is associated with post-pancreatectomy pancreatitis and the development of postoperative pancreatic fistula. <i>Hpb</i> , 2018, 20, 432-440.	0.3	45
20	TMIC-39. UNRAVELLING THE TUMOUR MICROENVIRONMENT OF GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi264-vi265.	1.2	0
21	Introduction to Mammalian Genome special issue: inflammation and immunity in cancer. <i>Mammalian Genome</i> , 2018, 29, 691-693.	2.2	0
22	Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment. <i>Frontiers in Oncology</i> , 2018, 8, 314.	2.8	43
23	BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. <i>PLoS ONE</i> , 2018, 13, e0203003.	2.5	10
24	The role of proteomics in the age of immunotherapies. <i>Mammalian Genome</i> , 2018, 29, 757-769.	2.2	12
25	Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration. <i>International Journal of Molecular Sciences</i> , 2018, 19, 205.	4.1	72
26	ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses. <i>Clinical Lung Cancer</i> , 2018, 19, 457-459.	2.6	8
27	P2.O1-012 Acquired Chemotherapy Resistance in vitro: miRNA Profiles of Chemotherapy Resistant Squamous Lung Cancer Cell Lines. <i>Journal of Thoracic Oncology</i> , 2017, 12, S790-S791.	1.1	3
28	Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. <i>Scientific Reports</i> , 2017, 7, 10374.	3.3	33
29	CBIO-10. GLIOBLASTOMA RECURRENCE CORRELATES WITH INCREASED APE1 AND AN IMMUNE-SUPPRESSION MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2017, 19, vi34-vi35.	1.2	2
30	29th International Mammalian Genome Conference meeting report. <i>Mammalian Genome</i> , 2016, 27, 169-178.	2.2	2
31	Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model. <i>Journal of Visualized Experiments</i> , 2015, . .	0.3	2
32	The Extracellular Matrix in Epithelial Ovarian Cancer – A Piece of a Puzzle. <i>Frontiers in Oncology</i> , 2015, 5, 245.	2.8	101
33	Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors. <i>Hormones and Cancer</i> , 2015, 6, 142-152.	4.9	1
34	Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. <i>Proteomics - Clinical Applications</i> , 2015, 9, 1078-1086.	1.6	7
35	Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 1-19.	2.8	23
36	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. <i>Oncotarget</i> , 2015, 6, 44551-44562.	1.8	37

#	ARTICLE	IF	CITATIONS
37	Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines. <i>Cancer Immunology Research</i> , 2014, 2, 469-479.	3.4	22
38	Genetically Engineered Insertional Mutagenesis in Mice to Model Cancer: Sleeping Beauty. <i>Methods in Molecular Biology</i> , 2014, 1194, 367-383.	0.9	4
39	From mice to men: GEMMs as trial patients for new NSCLC therapies. <i>Seminars in Cell and Developmental Biology</i> , 2014, 27, 118-127.	5.0	19
40	Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet?. <i>Seminars in Cell and Developmental Biology</i> , 2014, 27, 106-117.	5.0	19
41	Mice and men working together for over 100 years in the fight against cancer. <i>Seminars in Cell and Developmental Biology</i> , 2014, 27, 52-53.	5.0	0
42	Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. <i>Scientific Reports</i> , 2014, 4, 6152.	3.3	20
43	Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. <i>Translational Oncology</i> , 2013, 6, 742-IN34.	3.7	31
44	Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6091-6096.	7.1	19
45	Low-Dose Spironolactone Prevents Apoptosis Repressor With Caspase Recruitment Domain Degradation During Myocardial Infarction. <i>Hypertension</i> , 2012, 59, 1164-1169.	2.7	37
46	Sleeping Beauty – A mouse model for all cancers?. <i>Cancer Letters</i> , 2012, 317, 1-8.	7.2	19
47	CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. <i>Endocrine-Related Cancer</i> , 2010, 17, 273-282.	3.1	37
48	Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 434-441.	3.6	120
49	A Targeted Deleterious Allele of the Splicing Factor SCNM1 in the Mouse. <i>Genetics</i> , 2008, 180, 1419-1427.	2.9	8
50	Evidence for a direct role of the disease modifier SCNM1 in splicing. <i>Human Molecular Genetics</i> , 2007, 16, 2506-2516.	2.9	41
51	Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 377-392.	1.6	21
52	Rapid Mutation Screening for HRPT2 and MEN1 Mutations Associated with Familial and Sporadic Primary Hyperparathyroidism. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 559-566.	2.8	16
53	Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1140-1149.	3.7	213
54	Gene Expression of Parathyroid Tumors. <i>Cancer Research</i> , 2004, 64, 7405-7411.	0.9	96

#	ARTICLE	IF	CITATIONS
55	A molecular diagnosis of hyperparathyroidismâ€”jaw tumor syndrome in an adolescent with recurrent kidney stones. <i>Journal of Pediatrics</i> , 2004, 145, 567.	1.8	16
56	Rapid Mutation Scanning of Genes Associated with Familial Cancer Syndromes Using Denaturing High-Performance Liquid Chromatography. <i>Neoplasia</i> , 2001, 3, 236-244.	5.3	31
57	The Tayâ€”Sachs disease prevention program in Australia: Sydney pilot study. <i>Medical Journal of Australia</i> , 1995, 163, 298-300.	1.7	19